Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics is a promising biotechnology company with a differentiated niche in the regenerative medicine sector, leveraging fibroblasts as a therapeutic engine. Its deep intellectual property moat, with over 275 issued and pending patents, provides a strong foundation for its development of fibroblast-based therapies for various chronic diseases. Near-term catalysts to monitor include the ongoing Phase 1/2 trial for CYWC628 in diabetic foot ulcers, progress in its burn program, and further validation of its fibroblast spheroid biology across wound indications. While the recent reverse stock split may lead to short-term investor caution, the company's long-term potential remains intact.

Bears say

FibroBiologics is a clinical-stage biotechnology company with promising product candidates in the fields of wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. However, their lack of established commercial products and ongoing R&D investments may strain their financial resources. Additionally, the company's reliance on a single platform technology for all their product candidates poses significant risks and uncertainty for their future success.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.